Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jay D. Naik"'
Publikováno v:
Journal of Clinical Pathology. 65:580-584
Mucinous epithelial ovarian cancers (mEOC) are a relatively rare subset of ovarian cancers. Despite a relatively favourable outcome in early disease, the more frequent advanced presentation is associated with poorer response to platinum/taxane chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7e914cea8dbe9972ac3406f11701be
https://doi.org/10.1136/jclinpath-2011-200320
https://doi.org/10.1136/jclinpath-2011-200320
Publikováno v:
Clinical Cancer Research. 17:4214-4224
Oncolytic viruses consist of a diverse range of DNA and RNA viruses traditionally thought to mediate their effects by exploiting aberrations in tumor pathways, allowing preferential viral replication in, and killing of, tumor cells. Clinical developm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ad73b137282b92bb73dfdb67e45819
https://doi.org/10.1158/1078-0432.ccr-10-2848
https://doi.org/10.1158/1078-0432.ccr-10-2848
Autor:
Jian Qiao, Jay D. Naik, John C. Bell, Hongxun Wang, K.J. Harrington, Kelley Parato, Timothy Kottke, Richard G. Vile, Candice Willmon, Andrew W. Hudacek, Jill Thompson, Rosa Maria Diaz, Alan Melcher, John D. Chester, Peter Selby
Publikováno v:
Gene Therapy. 15:604-616
Although adoptive T-cell therapy has shown clinical success, efficacy is limited by low levels of T-cell trafficking to, and survival in, the immunosuppressive environment of an established tumor. Oncolytic virotherapy has recently emerged as a promi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e3c04928b6ae93a55e20118c78b6b75
https://doi.org/10.1038/sj.gt.3303098
https://doi.org/10.1038/sj.gt.3303098
Autor:
Tomohisa Saito, Chris Twelves, Janet A Hartley, Donna Crawford, Masaichi Abe, Keith Jones, Iain R. Macpherson, Thomas Jeff Evans, Masanori Miwa, John M Hartley, D. Alan Anthoney, Jay D. Naik
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 536 (2012)
BMC Cancer
BMC Cancer
Background A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::910700855e051c312492ecf91c882808
http://www.biomedcentral.com/1471-2407/12/536
http://www.biomedcentral.com/1471-2407/12/536
Autor:
Christopher Bradley, S Michael Crawford, Julia Brown, Ivo M. Hennig, David Alan Anthoney, Alex J Szubert, Alan M. Melcher, Jay D. Naik, Matthew T. Seymour, David A. Jackson, Sarah Brown
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(20)
Purpose Options for single-agent fluoropyrimidine adjuvant therapy after bowel cancer resection include intravenous fluorouracil with leucovorin (FU/LV) or oral capecitabine. These treatments have similar efficacy but differ in convenience and toxici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ee8da1360ad3438e563ab8f2fda724
https://pubmed.ncbi.nlm.nih.gov/18612156
https://pubmed.ncbi.nlm.nih.gov/18612156
Autor:
Johnathan Joffe, John D. Chester, Loaie M. El-Helw, Robert E. Coleman, Peter Selby, Jay D. Naik
Publikováno v:
BJU international. 98(3)
OBJECTIVE: To report our experience of high-dose chemotherapy (HDC) with haematopoietic stem-cell support (HSC) in patients with poor risk, relapsed or refractory germ cell tumours (GCTs), as this treatment might offer effective salvage for patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1819cf458e68b1b1a7ea72b4cb2d0f
https://pubmed.ncbi.nlm.nih.gov/16925746
https://pubmed.ncbi.nlm.nih.gov/16925746
Publikováno v:
Journal of Clinical Pathology; Jul2012, Vol. 65 Issue 7, p580-584, 5p